NCT00057941View on ClinicalTrials.gov

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Estrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer

Interventions

DRUG

anastrozole

Given orally

DRUG

gefitinib

Given orally

DRUG

fulvestrant

Given intramuscularly

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00057941 - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter